Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip C Prorok

Showing results (11-20 of 82) with videos related to

Pageof 9
Sort By:
Biometrical Journal. Biometrische Zeitschrift|May 19, 2015
Quantification of length-bias in screening trials with covariate-dependent test sensitivitySonya L Heltshe, Karen Kafadar, Philip C Prorok
BMC Medical Research Methodology|September 20, 2002
Statistical issues in randomized trials of cancer screeningStuart G Baker, Barnett S Kramer, Philip C Prorok
Journal of the National Cancer Institute|November 3, 2014
Lead time and overdiagnosisStuart G Baker, Philip C Prorok, Barnett S Kramer
Disease Markers|August 24, 2004
Development tracks for cancer prevention markersStuart G Baker, Barnett S Kramer, Philip C Prorok
Journal of the National Cancer Institute|November 9, 2017
Editorial: Challenges in Quantifying OverdiagnosisStuart G Baker, Philip C Prorok, Barnett S Kramer
The New England Journal of Medicine|March 30, 2017
Prostate Cancer Screening - A Perspective on the Current State of the EvidencePaul F Pinsky, Philip C Prorok, Barnett S Kramer
BMC Medical Research Methodology|May 20, 2004
Comparing breast cancer mortality rates before-and-after a change in availability of screening in different regions: extension of the paired availability designStuart G Baker, Barrett S Kramer, Philip C Prorok
The New England Journal of Medicine|June 15, 2017
Prostate Cancer ScreeningPaul F Pinsky, Philip C Prorok, Barnett J Kramer
Journal of Medical Screening|September 24, 2015
Study designs for determining and comparing sensitivities of disease screening testsPhilip C Prorok, Barnett S Kramer, Anthony B Miller
The New England Journal of Medicine|January 5, 2017
Breast-Cancer Tumor Size and Screening EffectivenessH Gilbert Welch, Philip C Prorok, Barnett S Kramer
Pageof 9

Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
Biometrical Journal. Biometrische Zeitschrift|May 19, 2015
Quantification of length-bias in screening trials with covariate-dependent test sensitivitySonya L Heltshe, Karen Kafadar, Philip C Prorok
BMC Medical Research Methodology|September 20, 2002
Statistical issues in randomized trials of cancer screeningStuart G Baker, Barnett S Kramer, Philip C Prorok
Journal of the National Cancer Institute|November 3, 2014
Lead time and overdiagnosisStuart G Baker, Philip C Prorok, Barnett S Kramer
Disease Markers|August 24, 2004
Development tracks for cancer prevention markersStuart G Baker, Barnett S Kramer, Philip C Prorok
Journal of the National Cancer Institute|November 9, 2017
Editorial: Challenges in Quantifying OverdiagnosisStuart G Baker, Philip C Prorok, Barnett S Kramer
The New England Journal of Medicine|March 30, 2017
Prostate Cancer Screening - A Perspective on the Current State of the EvidencePaul F Pinsky, Philip C Prorok, Barnett S Kramer
BMC Medical Research Methodology|May 20, 2004
Comparing breast cancer mortality rates before-and-after a change in availability of screening in different regions: extension of the paired availability designStuart G Baker, Barrett S Kramer, Philip C Prorok
The New England Journal of Medicine|June 15, 2017
Prostate Cancer ScreeningPaul F Pinsky, Philip C Prorok, Barnett J Kramer
Journal of Medical Screening|September 24, 2015
Study designs for determining and comparing sensitivities of disease screening testsPhilip C Prorok, Barnett S Kramer, Anthony B Miller
The New England Journal of Medicine|January 5, 2017
Breast-Cancer Tumor Size and Screening EffectivenessH Gilbert Welch, Philip C Prorok, Barnett S Kramer
Pageof 9